Campath Maintenance in Chronic Lymphocytic Leukemia

• Status: Terminated
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study designed to test whether giving campath (also known as alemtuzumab) on a maintenance schedule will prolong the time until the patient requires chemotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Collaborator: Bayer
• Treatments: Alemtuzumab

Criteria

Inclusion Criteria:

• Enrollment in this study is open to patients 18 years of age with confirmed chronic lymphocytic leukemia, a clinical response of stable disease or better to previous treatment, and an Eastern Cooperative Oncology Group performance status of 0-2

Exclusion Criteria:

• Treatment failure in more than 3 prior regimens

• Active secondary malignancy

• Central nervous system involvement with CLL

• History of significant allergic reaction to antibody therapies that required discontinuation of the antibody therapy

• History of HIV positivity

• Hepatitis C virus (HCV) positivity based upon core antigen testing

• Active infection, requiring treatment with antibiotic, antiviral, or antifungal agents

• Pregnancy or lactation

• Other severe, concurrent diseases or mental disorders